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Type 1 diabetes (T1D), a disease defined by absolute insulin deficiency, is considered a 
chronic autoimmune disorder resulting from the destruction of insulin-producing 
pancreatic β cells (1).  The incidence of childhood-onset T1D has been increasing at a 
rate of 3-5% per year globally (2).  Despite the introduction of an impressive array of 
therapies aimed at improving disease management, no means for a practical “cure” 
exist (3).  This said, hope remains high that any of a number of emerging technologies 
(e.g. continuous glucose monitoring [CGM], insulin pumps, smart algorithms), 
alongside advances in stem cell biology, cell encapsulation methodologies and 
immunotherapy will eventually impact the lives of those with recently diagnosed or 
established T1D.  However, efforts aimed at reversing insulin dependence do not 
address the obvious benefits of disease prevention.  Hence, key “stretch goals” for T1D 
research include identifying improved and increasingly practical means for diagnosing 
the disease at earlier stages in its natural history (i.e., early, pre-symptomatic diagnosis), 
undertaking such efforts in the population at large to optimally identify those with pre-
symptomatic T1D, and introducing safe and effective therapeutic options for 
prevention.   
 
What Does “an Early, Pre-Symptomatic Diagnosis of T1D” Mean?  
The traditional diagnosis of T1D based on persistent hyperglycemia is preceded by a 
variable (many months to years) period of asymptomatic β cell autoimmunity (1).  
Research efforts over the last three decades involving literally millions of individuals, 
have established a paradigm for diagnosing β cell autoimmunity, based on analysis of 
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T1D-associated autoantibodies (AAb) against insulin, glutamic acid decarboxylase, 
insulinoma-associated protein 2 and zinc transporter 8 (4, 5).  These efforts have 
demonstrated that T1D-associated AAb are diagnostic and that children with multiple 
AAb progress to symptomatic diabetes at a rate approximating 11% per year (6).   
In contrast to the traditional diagnosis of T1D, an emerging concept embraces the 
impact of the aforementioned high rate of progression to overt hyperglycemia in 
children with multiple AAb (7).  This proactively posits that these children do, in effect, 
have T1D, but it is “pre-symptomatic,” that T1D is primarily an immune disorder and 
secondarily a metabolic one. Adoption of this concept by the health care community 
would not only provide a unique opportunity for an earlier diagnosis of T1D but in 
addition, open up new opportunities for prevention-directed therapies.  
 
How Do We Implement T1D Early Diagnosis for Prevention? 
One key initial question arising from this line of thought is, “What efforts are needed to 
enable the diagnosis of T1D at the pre-symptomatic stage, beyond the confines of affected 
families, in other words, in the general population?”  
This is an important question because most studies on the prediction and 
prevention of T1D to date have involved “enriched populations”, namely, relatives of a 
T1D proband, and subjects identified from the general population carrying HLA 
haplotypes known to confer high T1D risk. While the enriched population approach in 
relatives has advantages in terms of specificity and the ability to recruit participants, it 
markedly restricts the number of individuals who might theoretically benefit from early 
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diagnosis because, at best, it only captures 10-15% of those likely to develop T1D (8).  
Stated another way, by limiting efforts to relatives, we ignore up to 90% of the emerging 
T1D population - a major missed opportunity where the impact of prevention would be 
profound (Figure 1). Moreover, studies of relatives are a challenge as, even with an 
exceptional network for T1D prevention trials in place (e.g. NIH TrialNet, 
www.diabetestrialnet.org; EURODIAB ENDIT 
http://cordis.europa.eu/project/rcn/38525_en.html), recruitment to a multi-center 
trial of oral insulin in relatives with β cell autoimmunity took seven years to meet its 
enrollment targets.   
This notion of establishing programs that target the general population has been 
facilitated by an increasing understanding of the pre-symptomatic phase of T1D.  
TrialNet natural history studies have emphasized the importance of implementing early 
screening: cumulative autoantibody seroconversion was greatest and costs associated 
with autoantibody detection were lowest in subjects under ten years of age at the time 
of first screen (Vehik et al). Prospective studies from birth found that β cell 
autoimmunity was detectable between six months and five years of age in around 70% 
of children diagnosed with T1D (9-11). With the logistics of early diagnosis largely laid 
out by these natural history studies, we believe it is timely, and indeed obligatory, in 
order to translate potential preventative therapies, to expand screening for 
asymptomatic T1D in young children from relatives into the general population. For the 
smaller fraction of patients who develop autoimmunity during the teenage years, repeat 
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screening may be beneficial, but further discussions of cost and equipoise would likely 
be needed. 
 
The Challenge of Having a Diagnosis but No Treatment  
T1D researchers are faced with a dilemma. Through screening for AAb, we can identify 
children with impending disease but currently cannot stop the progression to T1D. Why 
then would one diagnose pre-symptomatic T1D? We would argue that it is the first and 
essential step in reaching effective treatment. Through studies of immunometabolism in 
AAb positive subjects, it is possible—perhaps even likely— that novel targets for 
prevention will be identified given the intrinsic nature of the disease occurring at the 
intersection of metabolism and immunity. We propose that rather than debating the 
screening of relatives versus the general population, we should make a sustained effort 
to screen for pre-symptomatic T1D in both groups. With careful and ethical approaches 
to screening and testing possible interventions, and as long as we do not raise 
expectations that prevention and ‘cure’ are just around the corner, we argue for 
diagnosis of pre-symptomatic T1D in the general population and attempts to find a 
means to delay or prevent the need for insulin treatment.  
There are indications that therapeutic intervention in pre-symptomatic T1D may 
have a higher likelihood of success than at the time of clinical diagnosis.  Results from 
an anti-CD3 antibody trial, although in recently-diagnosed T1D, suggest that those with 
a higher concentration of plasma C-peptide at study entry are more likely to be 
therapeutic “responders” (12). By extrapolation, we surmise that individuals at the pre-
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symptomatic stage with presumably even greater β cell function may be more 
responsive to immunotherapeutic approaches. Moreover, the rate of progression to T1D 
is considerably faster in children than adults, implying that trials in childhood will 
require fewer participants or at least similar numbers where the statistical power will be 
much greater. A child is not a “little adult,” and therapies should not necessarily be 
evaluated in adults in order to be applied in children, either for safety or efficacy. The 
provision of careful and informed counseling for participating children and their 
families is crucial.  
Coming to terms with the concept that clinical presentation of T1D is the end-
stage of pathology and that effective intervention for prevention must occur in early, 
pre-symptomatic disease is the important challenge. Current state of the art may not yet 
allow us to provide the pre-symptomatic T1D patient a credible offer to accept 
experimental treatment given the possibility that the individual may be among the 
minority who have multiple AAb but never develop symptomatic disease combined 
with potential side effects of therapy. Thus, we need to implement a new approach to 
developing experimental therapies and methods that could form the basis for disease 
mechanism-based clinical research trials, through which we understand in much 
greater detail than previously, the on-target and off-target effects of potential 
therapeutics, drug pharmacokinetics and pharmacodynamics, appropriate dosing 
regimens, and a commitment to understanding the long-term effects of drug(s) on the 
immune system and β cell health.  To achieve this, we must commit ourselves to 
identifying therapies that are appropriate for testing in pre-symptomatic children, in 
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whom a therapy should preserve β cell mass and function while maintaining immune 
defenses against infection and not adversely affecting the efficacy of vaccination. It 
therefore behooves us, to make the case that pre-symptomatic T1D is the time for 
participation in clinical trials.  This will have to be accepted by the T1D community of 
families, care givers, support organizations and researchers before regulatory bodies 
can be expected to play their part in facilitating trials in pre-symptomatic disease and 
before industry sees the feasibility and potential rewards.  
While we wait for a treatment that prevents or delays the onset of clinical T1D, 
we should be reminded of one largely underestimated, beneficial clinical outcome that 
early diagnosis of T1D offers, namely, the prevention of metabolic decompensation and 
diabetic ketoacidosis (13, 14).  Diabetic ketoacidosis occurs in 30% of children with acute 
onset of T1D. Natural history studies have demonstrated that testing for asymptomatic 
T1D can significantly reduce the prevalence of ketoacidosis and may also reduce 
depression, anxiety and burden in the family associated with the acute onset 
symptomatic T1D (15-17). Additionally, early intensive insulin treatment has been 
shown to beneficially affect subsequent glycemic control and reduce risk of long-term 
micro- and macrovascular disease (Silverstein et al. Diabetes Care 2005. Care of 
Children and Adolescents with T1D). While the societal benefits of saving lives and 
preventing diabetic ketoacidosis are without question, the economic benefits are 
uncertain (18), and in the absence of diabetes prevention, formal studies to assess the 
economic benefit of early diagnosis are required. To this end, the ability to implement 
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affordable point of care measurement at childhood visits would improve the cost 
efficiency of screening. 
 
The Way Forward  
While the established systems for pre-symptomatic T1D diagnosis are clearly key, how 
do we raise awareness and acceptance of their implementation into more routine 
clinical care and, at the same time, increase the likelihood that T1D prevention will be 
achieved? First, given the aforementioned arguments, we would propose that screening 
efforts be broadened beyond first-degree relatives to the general population. This could 
be achieved either by large-scale AAb screening of individuals in specific age ranges or 
through an approach that utilizes a combination of genetic analysis and AAb testing. 
Emerging technologies involving blood spot or capillary blood collection (19), as well as 
improvements in T1D AAb detection and genetic typing (6, 20-23), render this feasible.  
Indeed, the recently formed "Früh erkennen – Früh gut behandeln" (Fr1da) study 
involving population-based screening for AAb in Bavarian children provides an 
example (24, 25).  How testing in the general population would be introduced will vary 
from country to country. In Germany, this has been added to routine yearly pediatric 
visits that occur between the ages of 2 and 5 years. Screening is optional and by 
informed consent, and the cost is a little of US$20 per tested child (24) The optimal age 
for a single T1D AAb screen will be a compromise between the sensitivity of detecting a 
large number of children who have already developed multiple AAbs (increased if 
screening is in older children) and the loss of sensitivity by missing cases of diabetes 
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that occur prior to screening (Figure 1). In the United States, the ‘Well-child visits’ 
scheduled at times after the peak AAb incidence seen around 1 to 2 years of age (9-11) 
may be the best and most practical to identify children with pre-symptomatic T1D, and 
there may be additional opportunities to combine testing for asymptomatic T1D with 
screening for other chronic childhood diseases such as celiac disease or familial 
hypercholesterolemia. Repeated screening at more than one time point (i.e. a second 
screening after school admission) is costly but would increase the sensitivity of the 
approach, since perhaps up to one-third of children and adolescents who develop pre-
symptomatic T1D may be missed by a single test.  
Next, authoritative bodies in the T1D community (e.g. ADA, EASD, JDRF, NIH) 
should be encouraged to standardize and implement guidelines for staging of pre-
symptomatic T1D as a framework for prevention. Awareness for the threat of acute 
onset T1D with the risk and complications of metabolic decompensation and diabetic 
ketoacidosis, and the clinical benefits of an early diagnosis should be emphasized. 
Industry should be encouraged to position pre-symptomatic T1D in their immune 
disorder portfolios.  Indeed, efforts need be directed at improving the attractiveness of 




Staging. We have biomarkers that are able to identify and stage pre-symptomatic T1D 
(4, 6). However, we need to translate these into tests that can be applied cheaply in large 
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numbers. While current assays are sensitive, specific, and standardized (26-28), they are 
expensive and labor intensive, or require large sample volumes limiting their utility. 
Two stage autoantibody testing that employs a cheap and sensitive screening assay 
followed by more elaborate confirmation assays in 1-2% of those screened is one 
approach that could be considered (25). Subsequent development of sensitive cheap 
point of care assays that can be performed locally on capillary blood could increase 
application of screening, and could reduce costs since the majority of samples would 
not require further processing, including shipping to central laboratories. With the 
commercial development of various rapid single-sample ELISA-based assays, this goal 
seems increasingly feasible. Similarly, simplification of metabolic assessment is 
required, as well as standardization of some of the measurements. Metabolic 
assessment is an important component of management as it not only informs us 
whether β cell function is impaired, but also stratifies time to symptomatic disease. 
Furthermore, we should aim to accurately assess if β cell function is improving or 
declining, independent of extrinsic influences. Metabolic assessment currently requires 
clinic visits and invasive methodology, and is, therefore, relatively expensive and 
performed infrequently. Measurements that can be applied frequently or even in real-
time should be considered and developed in order to increase our knowledge of 
metabolic function variation, trends, and changes in children with AAbs. 
 
Heterogeneity. Evidence continues to accumulate that T1D is a heterogeneous disorder, 
with respect to its immunogenetics and pathology (29-35), accounting for different 
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autoantigen specificities, rate of loss of β cell function and age at clinical presentation. 
Thus, biomarkers that define heterogeneity with respect to genetic susceptibility, target 
autoantigens, immune signature, β cell function and metabolic stress may all help in the 
eventual goal of precision therapy. 
 
Assessing therapy. Perhaps the most needed set of biomarkers required are those that 
will assess whether there is a metabolic or immunologic change induced by therapy. 
First, these biomarkers should be able to define whether the therapy is achieving its 
mechanistic objectives. For example, we should be able to measure whether antigen-
based therapies achieve a quantitative and/or qualitative change in the immune 
response to the antigen in a manner presumed to be beneficial. Second, biomarkers 
must be able to determine whether there is a reversal or stabilization of β cell 
autoimmunity, and whether β cell stress has been alleviated. These biomarkers, once 
established, must secure regulatory qualification as diagnostic or prognostic markers 
for disease progression in pre-symptomatic T1D. These considerations are important if 
we expect industry to engage in trials. While the notions of extended screening will 
reduce enrolment time, industry must be able to see that there are reliable short term 
outcome measures on which to base decisions for longer term investment that 
appropriately powered efficacy trials require.  
 
Implementing a Sustainable Program 
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While it is relatively straightforward to propose what is needed, it is always a challenge 
to successfully achieve it. We recommend that model testing programs for pre-
symptomatic T1D that are integrated into regular clinical care of children are 
commenced as a means to prevent metabolic decompensation and diabetic ketoacidosis, 
as well as depression, anxiety and burden associated with the acute onset of T1D. This 
can be facilitated by formally recognizing the multiple T1D AAb positive state as 
disease. Prevention and reversal of asymptomatic T1D requires sustainable long-term 
programs and commitment to funding of an intensive research portfolio, along with 
firm investment by industry. The latter will also be facilitated by recognizing the 
disease status pre-symptomatic T1D.  
 
Concluding Thoughts  
At present, the means for pre-symptomatic diagnosis and prediction of T1D are largely 
established, but prevention remains a challenge. Researchers active in the adoption of 
population-based screening efforts, as well as individuals who have been screened, and 
their family members, will need to understand the current inability to prevent while 
undergoing pre-symptomatic diagnosis. The way forward is, therefore, to significantly 
expand the concept and practice of early pre-symptomatic diagnosis and develop and 
apply existing therapeutic agents that can be tested in rationally designed pilot 
(mechanistic and safety) and efficacy trials. The goal is to diagnose T1D at its earliest 
detectable stage and intervene to prevent symptomatic disease.  Such actions will, 
without question, have a dramatic impact on clinical management of this disease. 
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Raise Acceptance for Testing and Early Pre-symptomatic  Diagnosis 
Obstacle Action 
Psychological burden of knowing 
disease risk 
Extend pre-diabetes expertise, teams, 
and teaching, including psychological 
counseling beyond research centers  
Costs  
• Who should pay?  
• Equipoise 
Economic modeling  
Inability to accurately predict time to 
clinical disease  
Identify markers for rapid disease 
progression 
Burden of blood draw  Minimize test volume  
Test quality  
• Accreditation 
• Certified status 
Commercialize and certify high 
throughput risk testing methods  
Acceptance by health care providers  
• Will they advise in favor of 
screening? 
Increase lay and general practitioners’ 
knowledge about T1D 
Fear of employment/occupational 
discrimination 
Address anti-discrimination laws  
 
Page 21 of 48





Raise Acceptance for Type 1 Diabetes Prevention  
and Broaden the Scope for How it May Occur 
Obstacle Action 
Insufficient awareness  
• Short and long term risk of DKA  
and that it can be prevented  
• DKA prevention can be an 
outcome of early screening 
Increase awareness of 
• DKA acute and long term risk 
• DKA prevalence 
Develop education program for early 
diagnosis and DKA prevention 
No evidence for efficient preventive 
therapy (except DKA prevention by 
monitoring)  
Develop path for faster trials and 
combinatorial treatments (faster 
recruitment, shorter trial duration, 
authority acceptance of combinations) 
Insufficient understanding for need of 
randomized trials and placebo 
treatment (encountered amongst the 
general practice pediatrician)  
Explore cross over design, at least for 
mechanistic studies 
Insufficient pipeline of therapies that 
could be tested in children  
Engage pharma and expertise from other 
autoimmune disease areas 
Lack of reproducible/universally 
acceptable biomarkers suggesting 
success in terms of pharmaceutical 
intervention 
Develop programs for biomarker 
development paralleling trial conduction  
Potential impact of disease 
heterogeneity on methods for 
prevention 
• Within a given population  
• Across different populations  
Address specific age groups and 
populations and develop more 
personalized therapies  
Standard challenges associated with 
controlled trials  
• Compliance 
• Dropout 
• Use of agents in control subjects 
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Limited interest by “big pharma” and 
other agencies in trials whose outcomes 
take extensive periods of time 
Interest pharma  
• Requires the identification of a 
market for prevention 
Need for large populations to identify a 
statistically significant effect 
• Not enough identified pre-
diabetes cases for rapid trial 
recruitment  
Broaden population-based screening 
beyond first degree relatives  
Lack of guidelines for standard care of 
pre-diabetes outside research setting  
Implement guidelines for early stages 
and prevention 
Costs of large trials and long-term 
commitment 
Develop sustainable long-term programs 
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Figure Legend  
Figure 1: Infographic of The Road to Type 1 Diabetes Prevention. Data presented in 
the graph were modeled on published multiple β cell AAb incidence and progression to 
diabetes studies (4, 9, 10) and refer to 1000 multiple β cell AAb positive cases expected 
to occur by age 20 years. Blue bars indicate the number of multiple β cell AAb positive 
children identified at each age who have not developed diabetes, and red bars indicate 
the number who have developed diabetes. 
Page 24 of 48
For Peer Review Only
Diabetes



































Facts:   Multiple ß-cell AAb are diagnositc of early type 1 diabetes 
              Most multiple ßa-cell AAb cases appear before age 5 
    Progression rate to diabetes is 10% (older) to 15% (younger) per year  
Age 3 to 10 years is an efficient window for  




Requirements:  Cost-effective efficient diagnostic test and strategy 
   Staging of glycemia (normal through to diabetic) 
   Stage-appropriate therapies for trials in 3 to 10 year olds 
   Biomarkers of progression and response to therapy 
   Alternative therapy for failures   
Age (years) 
The Road to Type 1 Diabetes Prevention 
Figure 1 
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Type 1 diabetes (T1D), a disease defined by absolute insulin deficiency, is considered a 
chronic autoimmune disorder resulting from the destruction of insulin-producing 
pancreatic β cells (1).  The incidence of childhood-onset T1D has been increasing at a 
rate of 3-5% per year globally (2).  Despite the introduction of an impressive array of 
therapies aimed at improving disease management, no means for a practical “cure” 
exist (3).  This said, hope remains high that any of a number of emerging technologies 
(e.g. continuous glucose monitoring [CGM], insulin pumps, smart algorithms), alongside 
advances in stem cell biology, cell encapsulation methodologies and immunotherapy 
will eventually impact the lives of those with recently diagnosed or established T1D.  
However, efforts aimed at reversing insulin dependence do not address the obvious 
benefits of disease prevention.  Hence, key “stretch goals” for T1D research include 
identifying improved and increasingly practical means for diagnosing the disease at 
earlier stages in its natural history (i.e., early, pre-symptomatic diagnosis), undertaking 
such efforts in the population at large to optimally identify those with pre-symptomatic 
T1D, and introducing safe and effective therapeutic options for prevention.   
 
What Does “an Early, Pre-Symptomatic Diagnosis of T1D” Mean?  
The traditional diagnosis of T1D based on persistent hyperglycemia is preceded by a 
variable (many months to years) period of asymptomatic β β-cell autoimmunity (1).  
Research efforts over the last three decades involving literally millions of individuals, 
have established a paradigm for diagnosing β β-cell autoimmunity, based on analysis of 
T1D-associated autoantibodies (AAb) against insulin, glutamic acid decarboxylase, 
insulinoma-associated protein 2 and zinc transporter 8 (4, 5).  These efforts have 
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demonstrated that T1D-associated AAb are diagnostic and that children with multiple 
AAb progress to symptomatic diabetes at a rate approximating 11% per year (6).   
In contrast to the traditional diagnosis of T1D, an emerging concept embraces 
the impact of the aforementioned high rate of progression to overt hyperglycemia in 
children with multiple AAb (7).  This proactively posits that these children do, in effect, 
have T1D, Ibut it is “pre-symptomatic,” that T1D is primarily an immune disorder and 
secondarily a metabolic one. Adoption of this concept by the health care community 
would not only provide a unique opportunity for an earlier diagnosis of T1D but in 
addition, open up new opportunities for prevention-directed therapies.  
 
How Do We Implement T1D Early Diagnosis for Prevention? 
One key initial question arising from this line of thought is, “What efforts are needed to 
enable the diagnosis of T1D at the pre-symptomatic stage, beyond the confines of 
affected families, in other words, in the general population?”  
This is an important question because most studies on the prediction and 
prevention of T1D to date have involved “enriched populations”, namely, relatives of a 
T1D proband, and subjects identified from the general population carrying HLA 
haplotypes known to confer high T1D risk.. While the enriched population approach in 
relatives has advantages in terms of specificity and the ability to recruit participants, it 
markedly restricts the number of individuals who might theoretically benefit from early 
diagnosis because, at best, it only captures 10-15% of those likely to develop T1D (8).  
Stated another way, by limiting efforts to relatives, we ignore up to 90% of the emerging 
T1D population - a major missed opportunity where the impact of prevention would be 
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profound (Figure 1). Moreover, studies of relatives are a challenge as, even with an 
exceptional network for T1D prevention trials in place (e.g. NIH TrialNet,; 
www.diabetestrialnet.org; EURODIAB ENDIT 
http://cordis.europa.eu/project/rcn/38525_en.html), recruitment to a multi-center trial of 
oral insulin in relatives with β β-cell autoimmunity took seven years to meet its 
enrollment targets.   
This notion of establishing programs that target the general population has been 
facilitated by an increasing understanding of the pre-symptomatic phase of T1D.  
TrialNet natural history studies have emphasized the importance of implementing early 
screening: cumulative autoantibody seroconversion was greatest and costs associated 
with autoantibody detection were lowest We now know that in subjects under ten years 
of age at the time of first screen (Vehik et al). Prospective studies from birth found thata 
majority of children diagnosed with T1D, β cell autoimmunity was detectable between 
six months and five years of age in around 70% of children diagnosed with T1D (9-11).  
With the logistics of early diagnosis largely laid out by these natural history studies, we 
believe it is timely, and indeed obligatory, in order to translate potential preventative 
therapies, to expand screening for asymptomatic T1D in young children from relatives 
into the general population. For the smaller fraction of patients who develop 
autoimmunity during the teenage years, repeat screening may be beneficial, but further 
discussions of cost and equipoise would likely be needed. 
 
The Challenge of Having a Diagnosis but No Treatment  
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T1D researchers are faced with a dilemma. Through screening for AAb, we can identify 
children with impending disease but currently cannot stop the progression to T1D. Why 
then would one diagnose pre-symptomatic T1D? We would argue that it is the first and 
essential step in reaching effective treatment. Through studies of immunometabolism in 
AAb positive subjects, it is possible—perhaps even likely— that novel targets for 
prevention will be identified given the intrinsic nature of the disease occurring at the 
intersection of metabolism and immunity. We propose that rather than debating the 
screening of relatives versus the general population, we should make a sustained effort 
to screen for pre-symptomatic T1D in both groups. With careful and ethical approaches 
to screening and testing possible interventions, and as long as we do not raise 
expectations that prevention and ‘cure’ are just around the corner, we argue for 
diagnosis of pre-symptomatic T1D in the general population and attempts to find a 
means to delay or prevent the need for insulin treatment.  
There are indications that therapeutic intervention in pre-symptomatic T1D may 
have a higher likelihood of success than at the time of clinical diagnosis.  Results from 
an anti-CD3 antibody trial, although in recently-diagnosed T1D, suggest that those with 
a higher concentration of plasma C-peptide at study entry are more likely to be 
therapeutic “responders” (12). By extrapolation, we surmise that individuals at the pre-
symptomatic stage with presumably even greater β β-cell function may be more 
responsive to immunotherapeutic approaches. Moreover, the rate of progression to T1D 
is considerably faster in children than adults, implying that trials in childhood will require 
fewer participants or at least similar numbers where the statistical power will be much 
greater. A child is not a “little adult,” and therapies should not necessarily be evaluated 
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in adults in order to be applied in children, either for safety or efficacy. The provision of 
careful and informed counseling for participating children and their families is crucial.  
Coming to terms with the concept that clinical presentation of T1D is the end-
stage of pathology and that effective intervention for prevention must occur in early, pre-
symptomatic disease is the important challenge. Current state of the art may not yet 
allow us to provide the pre-symptomatic T1D patient a credible offer to accept 
experimental treatment given the possibility that the individual may be among the 
minority who have multiple AAb but never develop symptomatic disease combined with 
potential side effects of therapy. ThusNext, we need to implement a new approach to 
developing experimental therapies and methods that could form the basis for disease 
mechanism-based clinical research trials, through which we understand in much greater 
detail than previously, the on-target and off-target effects of potential therapeutics, drug 
pharmacokinetics and pharmacodynamics, appropriate dosing regimens, and a 
commitment to understanding the long-term effects of drug(s) on the immune system 
and ββ cell health.  To achieve this, we must commit ourselves to identifying therapies 
that are appropriate for testing in pre-symptomatic children, in whom a therapy should 
preserve ββ cell mass and function while maintaining immune defenses against 
infection and not adversely affecting the efficacy of vaccination. It therefore behooves 
us, to make the case that pre-symptomatic T1D is the time for participation in clinical 
trials.  This will have to be accepted by the T1D community of families, care givers, 
support organizations and researchers before regulatory bodies can be expected to play 
their part in facilitating trials in pre-symptomatic disease and before industry sees the 
feasibility and potential rewards.  
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While we wait for a treatment that prevents or delays the onset of clinical T1D, 
we should be reminded of one largely underestimated, beneficial clinical outcome that 
early diagnosis of T1D offers, namely, the prevention of metabolic decompensation and 
diabetic ketoacidosis (13, 14).  Diabetic ketoacidosis occurs in 30% of children with 
acute onset of T1D. Natural history studies have demonstrated that testing for 
asymptomatic T1D can significantly reduce the prevalence of ketoacidosis and may also 
reduce depression, anxiety and burden in the family associated with the acute onset 
symptomatic T1D (15-17). Additionally, early intensive insulin treatment has been 
shown to beneficially affect subsequent glycemic control and reduce risk of long-term 
micro- and macrovascular disease (Silverstein et al. Diabetes Care 2005. Care of 
Children and Adolescents with T1D). While the societal benefits of saving lives and 
preventing diabetic ketoacidosis are without question, the economic benefits are 
uncertain (18), and in the absence of diabetes prevention, formal studies to assess the 
economic benefit of early diagnosis are required. To this end, the ability to implement 
affordable point of care measurement at childhood visits would improve the cost 
efficiency of screening. 
 
The Way Forward  
While the established systems for pre-symptomatic T1D diagnosis are clearly key, how 
do we raise awareness and acceptance of their implementation into more routine 
clinical care and, at the same time, increase the likelihood that T1D prevention will be 
achieved? First, given the aforementioned arguments, we would propose that screening 
efforts be broadened beyond first-degree relatives to the general population. This could 
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be achieved either by large-scale AAb screening of individuals in specific age ranges or 
through an approach that utilizes a combination of genetic analysis and AAb testing. 
Emerging technologies involving blood spot or capillary blood collection (19), as well as 
improvements in T1D AAb detection and genetic typing (6, 20-23), render this feasible.  
Indeed, the recently formed "Früh erkennen – Früh gut behandeln" (Fr1da) study 
involving population-based screening for AAb in Bavarian children provides an example 
(24, 25).(24).  How testing in the general population would be introduced will vary from 
country to country. In Germany, this has been added to routine yearly pediatric visits 
that occur between the ages of 2 and 5 years. Screening is optional and by informed 
consent, and the cost is a little of US$20 per tested child (24). The optimal age for a 
single T1D AAb screen will be a compromise between the sensitivity of detecting a large 
number of children who have already developed multiple AAbs (increased if screening 
is in older children) and the loss of sensitivity by missing cases of diabetes that occur 
prior to screening (Figure 1). In the United States, the ‘Well-child visits’ scheduled at 
times after the peak AAb incidence seen around 1 to 2 years of age (9-11) may be the 
best and most practical to identify children with pre-symptomatic T1D, and there may be 
additional opportunities to combine testing for asymptomatic T1D with screening for 
other chronic childhood diseases such as celiac disease or familial 
hypercholesterolemia. Repeated screening at more than one time point (i.e. a second 
screening after school admission) is costly but would increase the sensitivity of the 
approach, since perhaps up to one-third of children and adolescents who develop pre-
symptomatic T1D may be missed by a single test.  
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Next, authoritative bodies in the T1D community (e.g. ADA, EASD, JDRF, NIH) 
should be encouraged to standardize and implement guidelines for staging of pre-
symptomatic T1D as a framework for prevention. Awareness for the threat of acute 
onset T1D with the risk and complications of metabolic decompensation and diabetic 
ketoacidosis, and the clinical benefits of an early diagnosis should be emphasized. 
Industry should be encouraged to position pre-symptomatic T1D in their immune 
disorder portfolios.  Indeed, efforts need be directed at improving the attractiveness of 




Staging. We have biomarkers that are able to identify and stage pre-symptomatic T1D 
(4, 6). However, we need to translate these into tests that can be applied cheaply in 
large numbers. While current assays are sensitive, specific, and standardized (25-27), 
they are expensive and labor intensive, or require large sample volumes limiting their 
utility. Two stage autoantibody testing that employs a cheap and sensitive screening 
assay followed by more elaborate confirmation assays in 1-2% of those screened is one 
approach that could be considered (25). Subsequent development of sensitive 
cheapIdeally, we need point of care assays that can be performed locallyquickly on 
capillary blood could increase application of screening, and could reduce costs since . 
This is the majority of samples would not require further processing, including shipping 
to central laboratories. With the commercial development of various rapid single-sample 
ELISA-based assays, this goal seems increasingly feasible.first priority for future T1D 
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AAb assays. Similarly, simplification of metabolic assessment is required, as well as 
standardization of some of the measurements. Metabolic Ideally, metabolic assessment 
is an important component of management as it not would not only informsinform us 
whether β cell function is impaired, but also stratifiesstratify time to symptomatic 
disease. Furthermore, we should aim to accurately assess if β cell function is improving 
or declining, independent of extrinsic influences. Metabolic assessment currently 
requires clinic visits and invasive methodology, and is, therefore, relatively expensive 
and performed infrequently. Measurements that can be applied frequently or even in 
real-time should be considered and developed in order to increase our knowledge of 
metabolic function variation, trends, and changes in children with AAbs. 
 
Heterogeneity. Evidence continues to accumulate that T1D is a heterogeneous 
disorder, with respect to its immunogenetics and pathology (28-34), accounting for 
different autoantigen specificities, rate of loss of β cell function and age at clinical 
presentation. Thus, biomarkers that define heterogeneity with respect to genetic 
susceptibility, target autoantigens, immune signature, β cell function and metabolic 
stress may all help in the eventual goal of precision therapy. 
 
Assessing therapy. Perhaps the most needed set of biomarkers required are those that 
will assess whether there is a metabolic or immunologic change induced by therapy. 
First, these biomarkers should be able to define whether the therapy is achieving its 
mechanistic objectives. For example, we should be able to measure whether antigen-
based therapies achieve a quantitative and/or qualitative change in the immune 
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response to the antigen in a manner presumed to be beneficial. Second, biomarkers 
must be able to determine whether there is a reversal or stabilization of β cell 
autoimmunity, and whether β cell stress has been alleviated. These biomarkers, once 
established, must secure regulatory qualification as diagnostic or prognostic markers for 
disease progression in pre-symptomatic T1D. These considerations are important if we 
expect industry to engage in trials. While the notions of extended screening will reduce 
enrolment time, industry must be able to see that there are reliable short term outcome 
measures on which to base decisions for longer term investment that appropriately 
powered efficacy trials require.  
 
Implementing a Sustainable Program 
While it is relatively straightforward to propose what is needed, it is always a 
challenge to successfully achieve it. We recommend that model testing programs for 
pre-symptomatic T1D that are integrated into regular clinical care of children are 
commenced as a means to prevent metabolic decompensation and diabetic 
ketoacidosis, as well as depression, anxiety and burden associated with the acute onset 
of T1D. This can be facilitated by formally recognizing the multiple T1D AAb positive 
state as disease. Prevention and reversal of asymptomatic T1D requires sustainable 
long-term programs and commitment to funding of an intensive research portfolio, along 
with firm investment by industry. The latter will also be facilitated by recognizing the 
disease status pre-symptomatic T1D.  
 
Concluding Thoughts  
Formatted: Indent: First line:  0.49"
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At present, the means for pre-symptomatic diagnosis and prediction of T1D are largely 
established, but prevention remains a challenge. Researchers active in the adoption of 
population-based screening efforts, as well as individuals who have been screened, and 
their family members, will need to understand the current inability to prevent while 
undergoing pre-symptomatic diagnosis. The way forward is, therefore, to significantly 
expand the concept and practice of early pre-symptomatic diagnosis and develop and 
apply existing therapeutic agents that can be tested in rationally designed pilot 
(mechanistic and safety) and efficacy trials. The goal is to diagnose T1D at its earliest 
detectable stage and intervene to prevent symptomatic disease.  Such actions will, 
without question, have a dramatic impact on clinical management of this disease. 
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Raise Acceptance for Testing and Early Pre-symptomatic  Diagnosis 
Obstacle Action 
Psychological burden of knowing 
disease risk 
Extend pre-diabetes expertise, teams, 
and teaching, including psychological 
counseling beyond research centers  
Costs  
• Who should pay?  
• Equipoise 
Economic modeling  
Inability to accurately predict time to 
clinical disease  
Identify markers for rapid disease 
progression 
Burden of blood draw  Minimize test volume  
Test quality  
• Accreditation 
• Certified status 
Commercialize and certify high 
throughput risk testing methods  
Acceptance by health care providers  
• Will they advise in favor of 
screening? 
Increase lay and general 
practitioners’ knowledge about T1D 
Fear of employment/occupational 
discrimination 
Address anti-discrimination laws  
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Raise Acceptance for Type 1 Diabetes Prevention  
and Broaden the Scope for How it May Occur 
Obstacle Action 
Insufficient awareness  
• Short and long term risk of DKA  
and that it can be prevented  
• DKA prevention can be an 
outcome of early screening 
Increase awareness of 
• DKA acute and long term risk 
• DKA prevalence 
Develop education program for early 
diagnosis and DKA prevention 
No evidence for efficient preventive 
therapy (except DKA prevention by 
monitoring)  
Develop path for faster trials and 
combinatorial treatments (faster 
recruitment, shorter trial duration, 
authority acceptance of combinations) 
Insufficient understanding for need of 
randomized trials and placebo 
treatment (encountered amongst the 
general practice pediatrician)  
Explore cross over design, at least for 
mechanistic studies 
Insufficient pipeline of therapies that 
could be tested in children  
Engage pharma and expertise from 
other autoimmune disease areas 
Lack of reproducible/universally 
acceptable biomarkers suggesting 
success in terms of pharmaceutical 
intervention 
Develop programs for biomarker 
development paralleling trial conduction  
Potential impact of disease 
heterogeneity on methods for 
prevention 
• Within a given population  
• Across different populations  
Address specific age groups and 
populations and develop more 
personalized therapies  
Standard challenges associated with 
controlled trials  
• Compliance 
• Dropout 
• Use of agents in control subjects 
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Limited interest by “big pharma” and 
other agencies in trials whose 
outcomes take extensive periods of 
time 
Interest pharma  
• Requires the identification of a 
market for prevention 
Need for large populations to identify a 
statistically significant effect 
• Not enough identified pre-
diabetes cases for rapid trial 
recruitment  
Broaden population-based screening 
beyond first degree relatives  
Lack of guidelines for standard care of 
pre-diabetes outside research setting  
Implement guidelines for early stages 
and prevention 
Costs of large trials and long-term 
commitment 
Develop sustainable long-term programs 
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Figure Legend  
Figure 1: Infographic of The Road to Type 1 Diabetes Prevention. Data presented 
in the graph were modeled on published multiple β cell AAb incidence and progression 
to diabetes studies (4, 9, 10) and refer to 1000 multiple β cell AAb positive cases 
expected to occur by age 20 years. Blue bars indicate the number of multiple β cell AAb 
positive children identified at each age who have not developed diabetes, and red bars 
indicate the number who have developed diabetes. 
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